Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Cell-in-cell' mechanism explains how blood cancer uses bone marrow to evade treatment

2.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

3.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

4.

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

5.

The New Canadian Guidelines for Drinking at High Risk, AUD.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot